Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting Review

Release Date: August 30, 2019
Expiration Date: August 30, 2020
Media: Internet - based

Activity Overview

Community Practice Connections™: ASCO Direct™ Highlights ‒ 2019 Official Annual Meeting Review provides concise summaries and expert commentary on key clinical studies presented at the oncology meeting in June 2019. This activity includes interactive clinical vignettes and questions related to the application of recent clinical trials, followed by short video interviews with leading experts in the management of patients with cancer. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by healthcare professionals engaged in the care of patients with cancer.

Benefits of Participating

• Learn about the increasing role of molecular testing in patients with solid tumors
• Increase your knowledge of recent data influencing clinical practice
• Gain expert insights into emerging therapeutic approaches for patients with cancer

Acknowledgement of Commercial Support

This activity is supported by educational grants from Novartis Pharmaceuticals Corporation, Sanofi Genzyme, and Seattle Genetics, Inc.

Target Audience

This educational activity is directed toward medical oncologists, as well as surgical oncologists, nurses, and pathologists. Nurse practitioners, physician assistants, pharmacists, researchers, and other healthcare professionals may also participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Examine how tumor-testing strategies have been integrated into the study designs of recently reported clinical trials
• Apply tumor characteristics to identify patients who may benefit from emerging strategies for the treatment of solid and liquid malignancies
• Report recent clinical trial findings that have the potential to change clinical practice and optimize outcomes for patients with cancer
• Place recent trial evidence into the context of evolving treatment paradigms for cancer management

Faculty, Staff, and Planners’ Disclosures

Faculty

Saad Zafar Usmani, MD, FACP
Division Chief, Plasma Cell Disorders
Director, Clinical Research Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute
Atrium Health
Charlotte, NC

Disclosures: Grant/Research Support: Amgen, Array BioPharma, Bristol-Myers Squibb, Celgene, Janssen, Merck, Pharmacyclics, Sanofi; Consultant: AbbVie, Amgen, Celgene, Janssen, Merck, Seattle Genetics, SkylineDx, Takeda, GlaxoSmithKline; Speakers Bureau: Amgen, Celgene, Janssen, Takeda.

Earle Burgess, MD
Chief, Genitourinary Oncology Section
Levine Cancer Institute
Atrium Health
Charlotte, NC

Disclosures: Grant Research Support: Astellas, Pfizer; Consultant: Janssen.

Stephanie L. Graff, MD
Director, Breast Program
Sarah Cannon Cancer Institute
HCA Midwest Health
Associate Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Kansas City, MO

Disclosures: Dr. Stephanie L. Graff has no relevant financial relationships with commercial interests to disclose.

Melissa L. Johnson, MD
Associate Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, TN

Disclosures: Grant/Research Support: ALL TO INSTITUTION – AbbVie, Adaptimmune, Apexigen, Array BioPharma, AstraZeneca, BerGenBio, Checkpoint Therapeutics, EMD Serono, Genentech/Roche, Genmab, Janssen, Lilly, Mirati Therapeutics, Novartis, Pfizer, Regeneron, Stemcentrx, Syndax ,Tarveda; Consultant: Contract Lobbyist for Astellas, Contract Lobbyist for Otsuka Pharmaceuticals; Consultant (ALL TO INSTITUTION) – Araxes Pharma, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera, Celgene, Genentech/Roche, Guardant Health, Incyte, LOXO, Merck, Mersana, Mirati, Pfizer, Ribon Therapeutics, Sanofi; Other: Food/Beverage/Travel ‒ AbbVie, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, EMD Serono, Exelixis, Genentech, Incyte, Merck, Pfizer, Sysmex Inostics, Vapotherm, Mirati.

Meredith McKean, MD, MPH
Investigator, Melanoma and Skin Cancer Research Program
Sarah Cannon Research Institute
Nashville, TN

Disclosures: Dr. Meredith McKean has no relevant financial relationships with commercial interests to disclose.

Saurin A. Chokshi, MD
Medical Oncologist
Tennessee Oncology
Sarah Cannon Research Institute
Nashville, TN

Disclosures: Saurin Chokshi has no relevant financial relationships with commercial interests to disclose.

The staff of Physicians' Education Resource^®, LLC (PER^®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER^® is required by ACCME to resolve all COIs. PER^® has identified and resolved all COIs prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.